Erratum

'Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors' by

JS Meyer, M Province published in

BCRT 12(2): 191–204, 1988.

We regret that the last three lines of Table 1 and the titles of the lower panels of Fig. 4 of this paper contained errors as originally printed; the authors had provided corrections which were accidentally omitted. The two lower panels of Fig. 4 of course refer to Stage I, as correctly stated in the legend, not Stage II. The full correct version of Table 1 is printed below.

Table 1. Comparison of prognostic variables other than TLI at five years.

Class of patients and variable	No. patients	Absolute survival % $\pm$ SE*	P	Relapse-free survival % $\pm$ SE*	P
Histologic grade					
1	27	86 $\pm$ 8	0.06	72 $\pm$ 11	0.06
2	170	76 $\pm$ 4		66 $\pm$ 4	
3	510	67 $\pm$ 3		56 $\pm$ 3	
Nuclear grade					
1	133	86 $\pm$ 4	0.0002	80 $\pm$ 4	0.0004
2	215	72 $\pm$ 4		55 $\pm$ 4	
3	162	60 $\pm$ 5		54 $\pm$ 4	
Venous or lymphatic invasion at tumor-margin					
Present	139	58 $\pm$ 5	<0.0001	45 $\pm$ 5	<0.0001
Absent	379	77 $\pm$ 3		66 $\pm$ 3	
Estrogen receptor**					
0– 9 fm/mg	177	57 $\pm$ 5	0.001	54 $\pm$ 4	0.006
10–49 fm/mg	124	85 $\pm$ 4		67 $\pm$ 5	
50 + fm/mg	170	75 $\pm$ 4		62 $\pm$ 5	
Progesterone receptor**					
0– 9 fm/mg	210	78 $\pm$ 5	0.06 (NS)	61 $\pm$ 8	0.78 (NS)
10–49 fm/mg	66	78 $\pm$ 7		63 $\pm$ 8	
50 + fm/mg	140	68 $\pm$ 5		62 $\pm$ 6	

* Percent probability of survival $\pm$ standard error.

** In fmoles/mg cytosol protein.